Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Symbicort pMDI Clear all
Completed Phase 3 Interventional

A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients

NCT00206154
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Budesonide/formoterol pMDI, Budesonide pMDI, Formoterol Turbuhaler
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
143
States / cities
Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 140 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2009 · Synced Oct 17, 2026, 1:13 PM EDT
Completed Phase 4 Interventional Results available

Phase IV O2 Consumption Study in COPD Patients.

NCT02533505
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg Inhalation aerosol, Matching Placebo pMDI 160/4.5 μg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Hartford, Connecticut • Boston, Massachusetts • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Oct 17, 2026, 1:13 PM EDT
Completed Phase 3 Interventional

A Two-week Study Assessing the Onset of Effect Questionnaire (OEQ) Administered Daily Versus Weekly in Adult Subjects

NCT00449527
View directory record Official record
Conditions
Asthma
Interventions
Budesonide/formoterol pMDI, Budesonide HFA pMDI
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
44
States / cities
Tuscumbia, Alabama • Fort Smith, Arkansas • Long Beach, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2011 · Synced Oct 17, 2026, 1:13 PM EDT
Completed Phase 3 Interventional Results available

A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg

NCT02091986
View directory record Official record
Conditions
Asthma
Interventions
Symbicort pMDI, Budesonide pMDI
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years to 11 Years
Enrollment
882 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
59
States / cities
Hoover, Alabama • Montgomery, Alabama • Gilbert, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 17, 2026, 1:13 PM EDT
Completed Phase 2 Interventional Results available

A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy

NCT01136655
View directory record Official record
Conditions
Asthma
Interventions
80/2.25 μg Symbicort pMDI, 80/4.5 μg Symbicort pMDI, Foradil Aerolizer 12 μg, 40 μg budesonide HFA pMDI, placebo HFA pMDI
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years to 11 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Huntington, California • Long Beach, California • Mission Viejo, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Oct 17, 2026, 1:13 PM EDT
Active, not recruiting Phase 3 Interventional

Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

NCT06473779
View directory record Official record
Conditions
Severe Asthma
Interventions
Tezepelumab, Budesonide/formoterol, Albuterol/budesonide (AIRSUPRA®), Mannitol, Salbutamol
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 80 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Palmdale, California • Colorado Springs, Colorado • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 1:13 PM EDT
Completed Phase 3 Interventional Results available

A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents

NCT01444430
View directory record Official record
Conditions
Asthma
Interventions
Symbicort pMDI, budesonide pMDI
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
12,460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
160
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 157 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 17, 2026, 1:13 PM EDT
Completed Phase 1 Interventional

A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma

NCT07433569
View directory record Official record
Conditions
Asthma
Interventions
Budesonide/formoterol fumarate Aerosphere, Budesonide/formoterol fumarate pMDI
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
4 Years to 12 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
6
States / cities
Long Beach, California • Miami, Florida • Lafayette, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 17, 2026, 1:13 PM EDT
Completed Phase 3 Interventional

A Two-week Study Assessing the Onset of Effect Questionnaire Administered Pre-dose Versus Post-dose in Adult Subjects

NCT00449501
View directory record Official record
Conditions
Asthma
Interventions
Budesonide/formoterol pMDI, Budesonide HFA pMDI
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
46
States / cities
Muscle Shoals, Alabama • Little Rock, Arkansas • Anaheim, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2011 · Synced Oct 17, 2026, 1:13 PM EDT
Completed Phase 4 Interventional Results available

Adherence Study in COPD Patients

NCT02864342
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD
Interventions
Arm 1: BreatheMate device with application, Arm 2: BreatheMate device without application
Device
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Clearwater, Florida • Tampa, Florida • Marlton, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Oct 17, 2026, 1:13 PM EDT
Completed Phase 4 Interventional Results available

Phase4/Symbicort® Versus Pulmicort Flexhaler® in African Americans

NCT00702325
View directory record Official record
Conditions
Asthma
Interventions
Budesonide / formoterol fumarate (SYMBICORT), Budesonide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
57
States / cities
Pell City, Alabama • Bentonville, Arkansas • Hot Springs, Arkansas + 54 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2012 · Synced Oct 17, 2026, 1:13 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)

NCT04609878
View directory record Official record
Conditions
Asthma
Interventions
BGF MDI 320/28.8/9.6 μg, BGF MDI 320/14.4/9.6 μg, BFF MDI 320/9.6 μg, BFF pMDI 320/9 μg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 80 Years
Enrollment
2,274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
107
States / cities
Saraland, Alabama • Phoenix, Arizona • Sun City West, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 17, 2026, 1:13 PM EDT
Completed Phase 3 Interventional Results available

Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease

NCT02157935
View directory record Official record
Conditions
COPD Patients
Interventions
Symbicort, Formoterol turbohaler, Placebo for Symbicort pMDI, Placebo for Formoterol Turbohaler
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 95 Years
Enrollment
2,026 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
224
States / cities
Andalusia, Alabama • Birmingham, Alabama • Foley, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Oct 17, 2026, 1:13 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)

NCT04609904
View directory record Official record
Conditions
Asthma
Interventions
BGF MDI 320/28.8/9.6 μg, BGF MDI 320/14.4/9.6 μg, BFF MDI 320/9.6 μg, BFF pMDI 320/9 μg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 80 Years
Enrollment
2,187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
88
States / cities
Chandler, Arizona • Tempe, Arizona • Tucson, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 17, 2026, 1:13 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma

NCT00419757
View directory record Official record
Conditions
Asthma
Interventions
Budesonide/formoterol (SYMBICORT) pMDI, Budesonide HFA pMDI
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
32
States / cities
Anaheim, California • Chula Vista, California • Fresno, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2012 · Synced Oct 17, 2026, 1:13 PM EDT
Completed Phase 3 Interventional Results available

New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day

NCT01360021
View directory record Official record
Conditions
Asthma
Interventions
Symbicort, Budesonide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
31
States / cities
Huntington Beach, California • Long Beach, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2014 · Synced Oct 17, 2026, 1:13 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparing Bronchodilation of Symbicort With and Without Valved Holding Chamber (Aerochamber Plus)

NCT00915538
View directory record Official record
Conditions
Asthma
Interventions
pMDI budesonide/formotrol 160/4.5 is in group 1, Symbicort 160/4.5 plus Aerochamber Plus included in group 2
Drug · Device
Lead sponsor
Western Sky Medical Research
Other
Eligibility
18 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Oct 17, 2026, 1:13 PM EDT
Completed Phase 3 Interventional Results available

Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/Formoterol Fumarate Dihydrate to Symbicort® in Asthmatic Participants

NCT02495168
View directory record Official record
Conditions
Asthma
Interventions
Generic Budesonide/Formoterol Fumarate Dihydrate, Symbicort® (Budesonide/Formoterol Fumarate Dihydrate), Placebo
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
1,714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
17
States / cities
Surprise, Arizona • Huntington Beach, California • San Jose, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Oct 17, 2026, 1:13 PM EDT
Completed Phase 3 Interventional

A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD

NCT00206167
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Budesonide/formoterol pMDI, Formoterol Turbuhaler
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
131
States / cities
Birmingham, Alabama • Huntsville, Alabama • Jasper, Alabama + 128 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2009 · Synced Oct 17, 2026, 1:13 PM EDT
Completed Phase 3 Interventional Results available

A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.

NCT00419952
View directory record Official record
Conditions
Asthma
Interventions
Budesonide/formoterol (SYMBICORT) pMDI, Budesonide HFA pMDI
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
122
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 119 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Oct 17, 2026, 1:13 PM EDT
Completed Phase 3 Interventional Results available

A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD

NCT00419744
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Budesonide/formoterol (SYMBICORT) pMDI, Formoterol Turbuhaler
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
92
States / cities
Jasper, Alabama • Mobile, Alabama • Tucson, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2010 · Synced Oct 17, 2026, 1:13 PM EDT
Not listed Phase 4 Interventional

Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS)

NCT00867737
View directory record Official record
Conditions
Asthma
Interventions
Advair HFA MDI 115/21, Symbicort 160/4.5 pMDI
Drug
Lead sponsor
Allergy and Asthma Center of El Paso
Other
Eligibility
12 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2009 · Synced Oct 17, 2026, 1:13 PM EDT